Overall verdict
Buy
6.8/10
1-year performance
+8.99%
Score breakdown
Up 9.0% over 1 year, 68% of the 52-week range.
Strongest: Profitability 8.4/10. Weakest: Financial strength 3.6/10.
18 analysts, target +0.1% vs the price.
Labcorp Holdings Inc. provides laboratory services. It operates in Diagnostics Laboratories and Biopharma Laboratory Services segments. The company offers various tests, such as blood chemistry analyses, urinalyses, blood cell counts, thyroid tests, PAP tests, hemoglobin A1C, PSA, tests for sexually transmitted diseases, vitamin D testing, microbiology cultures and procedures, and alcohol and other substance abuse tests.
It also provides specialty testing services comprising gene-based and esoteric testing ; advanced tests target specific diseases ; services related to anatomic pathology/oncology, cardiovascular disease, coagulation, diagnostic genetics, endocrinology, infectious disease, women's health, pharmacogenetics, parentage and donor testing, occupational testing service, medical drug monitoring services, chronic disease programs, and kidney stone prevention tests ;
and health and wellness services to employers and managed care organizations. In addition, it offers digital pathology solutions, a pathology platforms that support the digitization, centralized review, and sharing of pathology slides ; provider and payer digital platforms, an online applications for providers, MCOs, and ACOs ; online and mobile applications that enable patients to check offerings, schedule PSC visits, check-in upon PSC arrival, complete documentation, access tests and test results, and manage their accounts ;
and Generative AI enabled Test Selection, a generative AI enabled tool. It serves clients, third party, medicare/medicaid, patients, pharmaceutical, biotechnology, medical device, diagnostic companies, and CROs. It has a strategic collaboration with the Children's Hospital of Philadelphia to accelerate the discovery, development, and availability of pediatric diagnostics ; a strategic alliance with the National Association of Community Health Centers to support current and emerging clinical leaders through the NACHC Leadership Exchange for Chief Medical Officers ;
and Alliance for Clinical Trials in Oncology to advance national clinical trial for patients diagnosed with colorectal cancer. The company was founded in 1995 and is headquartered in Burlington, North Carolina.
Sector
Health Care
Industry
Health Care Providers and Services
Primary listing
Nyse
United States
CEO
Adam Schechter
Founded
1995
Employees
71 000
Revenue / employee
196 503 USD
Next earnings
October 29, 2026 (estimated)
Institutional holders
- BlackRock, Inc.8.27%
- VANGUARD CAPITAL MANAGEMENT LLC6.75%
- VICTORY CAPITAL MANAGEMENT INC6.09%
- STATE STREET CORP4.92%
- VANGUARD PORTFOLIO MANAGEMENT LLC4.63%
- Boston Partners3.84%
- Allspring Global Investments Holdings, LLC2.82%
- GEODE CAPITAL MANAGEMENT, LLC2.76%
- Select Equity Group, L.P.2.49%
- Other institutions57.25%
- Rest of the register0.18%
1053 13F filings as of June 30, 2026: US managers above $100M, filed up to 45 days after quarter end. No insiders, no retail. A share on loan is declared by its lender and by whoever bought it from the short seller, so the total can exceed 100%.
Research uses the underlying stock’s market history. The purchase quote is calculated separately when you review your order.
52-week high
341.80 USD
52-week low
244.52 USD
1-year performance
8.99%
Rising
Year-to-date performance
20.96%
Rising
Drawdown
-9.21%
Mild pullback
Position in the 52-week range
68% of range
Against the world ETF
Over 17 years, from September 2009 to August 2026, the share did not do better than the world ETF once risk is accounted for. It earned less, while shaking 1.9 times harder.
10,000 € placed at the end of September 2009 are worth today
| Labcorp Holdings | 63 652 € |
| World ETF | 74 620 € |
| S&P 500 | 123 025 € |
| Risk-free placement | 11 288 € |
The risk
- Shaking:the share moves 1.9 times as much as the world ETF.
- Worst fall:-46 % between February 2020 and March 2020. 10,000 € placed at the top fell to 5 381 €. The world ETF, at worst: -34 %. Back to its high in 8 months.
Labcorp Holdings earned less than the world ETF since 2009
Value of 10,000 euros placed at the end of September 2009, dividends reinvested, in euros
- Labcorp Holdings: 63 652 €
- World ETF: 74 620 €
- S&P 500: 123 025 €
- Risk-free placement: 11 288 €
Share price without dividends; the world ETF and the index reinvest theirs. A dividend payer is therefore understated here.
Based on past performance. This is not a recommendation.
Range: 264.89 USD - 278.65 USD (comparables only)
The price implies growth of 5.85% per year; the company grows at -8.01%.
Gross margin 26.8%, net margin 7.0%, ROIC 6.8%, ROE 11.7%.
Net margin
6.99%
Exceptional
Sector 3.21%|S&P 12.97%
Gross margin
26.82%
Fair
Return on equity (ROE)
11.74%
Exceptional
Sector 6.71%|S&P 16.52%
Return on invested capital (ROIC)
6.79%
Exceptional
Free cash flow margin (FCF)
8.05%
Fair
Profit-to-cash conversion (FCF conversion)
1.15x
Fair
Margin stability
3.9 pts
Steady
Revenue to net income
Growth
5.1/10Revenue up 5.8% over 1 year, -0.0% a year over 5, EPS -8.0% a year over 5.
Revenue (trailing 12 months)
14.3Md USD
Revenue growth (1y)
5.78%
Moderate
Revenue growth (3y)
17.60%
Solid
EPS growth (1y)
28.47%
Solid
EPS CAGR (5y)
-8.01%
Declining
EPS revisions (3 months)
1.96%
Revised up
Valuation
6.0/10P/E 25.7x, forward P/E 22.3x, EV/EBITDA 14.0x, PEG 0.77. The multiple sits in the 72th percentile of its own 5-year history.
P/E (TTM)
25.7x
Fair
Sector 30.9x|S&P 23.0x
Forward P/E
22.3x
Fair
EV / EBITDA
14.0x
Fair
Sector 12.6x|S&P 14.5x
PEG
0.77
Growth unpriced
Sector 0.75|S&P 0.86
Fair value (reverse DCF)
271.77 USD
Overvalued
P/E vs its own 5-year history
among the 28% highest valuations
Pricier than usual
Market cap
24.7Md USD
Financial strength
3.6/10Cash covers 2.1% of the debt, net debt/EBITDA 2.4x.
Net debt / EBITDA
2.4x
Tight
Gearing (net debt / equity)
76.82%
Tight
Cash
142M USD
Cash / market cap
0.58%
Stretched
Cash / total debt
2.10%
Stretched
Interest coverage
6.6x
Solid
Net debt
6.6Md USD
Equity
8.6Md USD
Closed daily candles, 2 years
Last close on September 24, 2026: 308.95 USD
- MM20321.96
- MM50316.34
- MM200278.96
- RSI 1441.3
Top panel: closed candles, 20, 50 and 200-day moving averages, with volume in grey. Bottom panel: 14-day RSI with dashed 30 and 70 levels.
200-day average slope, 1 month
+2.28%
200-day average slope, 3 months
+4.41%
50-day average slope, 1 month
+7.17%
Price structure
higher-low
Bullish RSI divergence
No
20-day volatility
1.64 % per day
Volatility change
+16.52%
Forecasts by fiscal year
| Fiscal year | EPS | Normalised EPS | Revenue | EBITDA | Net income |
|---|---|---|---|---|---|
| 2026 | 13.93 (8) | 18.35 (18) | 14 749 (16) | 2 574 (8) | 1 130 (6) |
| 2027 | 15.57 (8) | 19.84 (18) | 15 480 (16) | 2 737 (8) | 1 242 (6) |
Amounts in millions of USD, EPS in USD per share. In brackets, the number of analysts. Consensus as of September 24, 2026.
Same sub-industry: 77 companies behind the medians.
| # | Company | Code | Country | Overall / 10 | Fundamentals / 10 | Mkt cap | P/E | Net margin | Revenue growth | ROIC | Net debt / EBITDA | FCF yield | 1-year perf. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | HNGE | 7.2 | 6.6 | 7.4Md USD | 71.1x | 14.8 % | 53.0 % | 29.3 % | -3.8x | 3.8 % | 55.7 % | ||
| 2 | CI | 7.0 | 7.1 | 70.9Md USD | 11.1x | 2.3 % | 6.5 % | 9.3 % | 1.8x | 12.9 % | -8.0 % | ||
| 3 | LH | 6.8 | 6.0 | 24.7Md USD | 25.7x | 7.0 % | 5.8 % | 6.8 % | 2.4x | 4.7 % | 9.0 % | ||
| 4 | CVS | 6.6 | 5.9 | 110Md USD | 22.7x | 1.2 % | 7.2 % | 3.2 % | 4.1x | 10.7 % | 10.9 % | ||
| 5 | DVA | 6.5 | 6.4 | 11.7Md USD | 15.4x | 5.9 % | 5.2 % | 6.9 % | 4.5x | 13.8 % | 32.3 % | ||
| 6 | BTSG | 6.4 | 4.9 | 11.0Md USD | 41.7x | 1.7 % | 23.0 % | 5.7 % | 4.6x | 3.6 % | 102.1 % | ||
| 7 | DGX | 6.4 | 5.7 | 25.7Md USD | 24.7x | 9.2 % | 10.2 % | 7.9 % | 2.8x | 5.2 % | 26.9 % | ||
| 8 | FME | 5.3 | 6.7 | 12.0Md USD | 11.8x | 4.8 % | 1.4 % | 4.3 % | 2.7x | 17.0 % | -10.0 % | ||
| 9 | GH | 4.7 | 2.6 | 23.7Md USD | Not meaningful (loss) | -38.3 % | 44.3 % | -37.0 % | -1.5x | -1.0 % | 189.0 % |
